Browse News
Filter News
Found 10 articles
-
Dementia Discovery Fund invests in Amphista Therapeutics as it targets neurodegenerative diseases
12/13/2022
Amphista Therapeutics, a leader in next generation targeted protein degradation approaches, announced a Series B extension investment by the Dementia Discovery Fund.
-
Protein Sequencing Market Size to Hit Around USD 1.91 BN by 2030
10/26/2022
The global protein sequencing market was surpassed at USD 1.4 billion in 2021 and is expected to hit around USD 1.91 billion by 2030, growing at a CAGR of 3.51% from 2022 to 2030.
-
Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases
10/25/2022
Adrestia Therapeutics announced the appointment of Dr James Osborne as Head of Chemistry and the initiation of a multi-target partnership with Proteros biostructures GmbH to accelerate the discovery of first-in-class candidate drugs for intractable diseases.
-
Amgen opened a new research and development site in San Francisco Bay, while Enzo Biochem opened a 100,000 square foot laboratory and research facility in New York
-
Proxygen partnered with Germany-based Merck to jointly identify and develop molecular glue degraders for clinical research.
-
Bristol Myers Squibb announced it is extending and expanding its strategic partnership with Evotec in targeted protein degradation, marking its second protein degradation deal this month.
-
Amphista Therapeutics forged two significant protein degradation partnerships with big pharma. Wednesday, the U.K.-based company announced partnerships with both Bristol Myers Squibb and Merck KGaA that have a combined value of more than $2 billion.
-
Amphista Therapeutics Enters Strategic Collaboration with Merck for Discovery and Development of Targeted Protein Degradation Therapeutics
5/4/2022
Amphista and Merck will collaborate to leverage Amphista's proprietary Eclipsys™ TPD platform and generate novel protein degrading therapeutics in oncology and immunology.
-
Amphista Therapeutics Enters Strategic Collaboration with Bristol Myers Squibb for Discovery and Development of Targeted Protein Degradation Therapeutics
5/4/2022
Amphista and Bristol Myers Squibb to collaborate and leverage Amphista's proprietary Eclipsys™ targeted protein degradation platform to develop novel protein degrading therapeutics.
-
Amphista Therapeutics Appoints Dr Martin Pass as CDO
12/6/2021
Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Dr Martin Pass, as Chief Development Officer (CDO).